Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. Monday, June 3, 2013, 18 U.S. common stocks are scheduled to go ex-dividend. The dividend yields on these stocks range from 0.5% to 7.7%. All of these stocks can be found on our stocks going ex-dividend section of our dividend calendar. Highlighted Stocks Going Ex-Dividend Monday:
Owners of PDL BioPharma (NASDAQ: PDLI) shares as of market close today will be eligible for a dividend of 15 cents per share. At a price of $8.32 as of 9:35 a.m. ET, the dividend yield is 7.4%. The average volume for PDL BioPharma has been 1.8 million shares per day over the past 30 days. PDL BioPharma has a market cap of $1.1 billion and is part of the drugs industry. Shares are up 15.9% year to date as of the close of trading on Thursday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more. PDL BioPharma, Inc. engages in intellectual property asset management and patent portfolio and related assets investment activities. The company has a P/E ratio of 5.37. TheStreet Ratings rates PDL BioPharma as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, good cash flow from operations, solid stock price performance and impressive record of earnings per share growth. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full PDL BioPharma Ratings Report now.